Crossmark

Comparison of 1-year outcomes after switching to faricimab in neovascular age-related macular degeneration previously treated with anti-VEGF agents with/without a loading phase

Crossref DOI link: https://doi.org/10.1007/s10384-025-01258-4

Published Online: 2025-08-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hikichi, Taiichi

Kurabe, Haruka

Notoya, Amane

Oguro, Yuuna

Hirano, Misaki

Doi, Yumeka
License Information

Text and Data Mining valid from 2025-08-07

Version of Record valid from 2025-08-07
More Information

Article History

Received: 24 April 2025

Accepted: 8 July 2025

First Online: 7 August 2025

Declarations

:

: T. Hikichi, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Novartis, Bayer, Chugai); H. Kurabe, None; A. Notoya, None; Y. Oguro, None; M. Hirano, None; Y. Doi, None.

Document is current

Any future updates will be listed below